Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was up 7.5% in after-hours trading as of roughly 5:33 p.m. ET Wednesday after the FDA permitted Genglycos for glycogen storage illness sort Ia, or GSDIa. The one-time gene therapy is the first permitted remedy designed to deal with the disorder’s underlying cause. It will carry a U.S. record price of roughly $2.7 million per affected person and is expected to become obtainable through certified remedy facilities within 30 to 60 days.
The approval gives Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) first-mover standing in a illness the company estimates impacts only 1,500 to 2,500 Americans. The business query is whether a high-priced remedy for an ultra-rare population can produce significant income after diagnosis, reimbursement, and treatment-center constraints.
BULL CASE: A Meaningful Benefit Supports Premium Pricing
GSDIa prevents the liver from releasing glucose correctly, leaving sufferers dependent on frequent raw-cornstarch doses to keep away from doubtlessly life-threatening hypoglycemia. In the Phase 3 GlucoGene trial, Genglycos diminished imply every day cornstarch consumption by 41% at Week 48, in contrast with 10% for placebo, while sustaining glucose control. For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), decreasing that every day burden creates a clear argument for premium pricing.
Longer-term knowledge also support the remedy’s potential sturdiness. At Week 96, the original-treatment group reported a 61% imply discount from baseline, while the crossover group reported a 61% discount from Week 48, when it started remedy. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will manufacture the therapy at its Bedford, Massachusetts, facility, giving the company direct control over an important half of the provide chain.
The launch will also take a look at infrastructure that could support future gene therapies. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) already sells rare-disease merchandise including Crysvita, Dojolvi, Evkeeza and Mepsevii. Second-quarter income reached $214 million, while money, money equivalents, and marketable securities totaled $436 million as of June 30. Genglycos therefore enters a functioning business group rather than a first-time launch platform.
BEAR CASE: The Addressable Market Is Exceptionally Small
The $2.7 million record price creates substantial potential gross income per affected person before payer reductions, rebates, and access preparations. However, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) must find eligible sufferers, secure payer approval, and transfer them through certified remedy facilities. The complete addressable population is already small, and annual demand could decline after the initial pool of recognized sufferers receives a one-time therapy.